

The Board of Pharmacy has received notice of the following product withdrawal. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

CSL Behring has instituted a withdrawal of one (1) lot of HIZENTRA at the PATIENT level due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration. Injection-site reactions and hypersensitivity are a known risk with subcutaneous Immune Globulin products.

The table below indicates the impacted lot of HIZENTRA, which was shipped from CSL Behring in September 2021:

Hizentra® 20% (10g/50 mL)

NDC: 44206-0455-10

LOT	EXPIRY DATE
P100340460	12-NOV-2023